Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTM-N2D · 1 trial · 4 indications
Cohort 1: Three patients will be treated with four escalating doses of CTM-N2D to determine an optimal dose based on the incidence of DLT. DLT is defined as an unexpected grade 3 or 4 non-hematologic toxicity that is probably related to CTMN2D infusion and experienced within 8 weeks immediately after the start of study treatment. Treatments with maintenance doses of CTM-N2D will not be considered in determining DLT.
Cohort 2: Six patients will be treated with four infusions of CTM-N2D at the optimal dose determined in Cohort 1.
| Arm | Type | Description |
|---|---|---|
| Dose-Escalation Arm | EXPERIMENTAL | Four infusions of CTM-N2D at escalating doses: 1x10\^7, 1x10\^8, 3x10\^8 or 1x10\^9 per infusion at an interval of one infusion every 7 days. |
| Optimal Dose Arm | EXPERIMENTAL | Four infusions of CTM-N2D at the optimal dose (expected to be 1x10\^9) at an interval of one infusion every 7 days. |
| Name | Type | Description |
|---|---|---|
| Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) | BIOLOGICAL | In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients. |
Inclusion Criteria: * At least 21 years of age * Provision of signed and dated, written informed consent prior to any study specific procedures, sampling, and analyses (if applicable, the written informed consent may include access to all archival tumour tissue, e.g., diagnostic and/or most recent ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
CTM-N2D is an investigational allogeneic cell therapy being developed for advanced cancers. It is a CAR-grafted gamma delta T cell product designed to target NKG2DL. It is currently in Phase 1 clinical development and is not approved for any indication.
CTM-N2D is being studied for the treatment of advanced cancers, including refractory and relapsed malignancies. The Phase 1 trial enrolls patients with cancer, malignancy, refractory cancer, or relapsed cancer. It is investigational and has not been approved for any use.
CTM-N2D targets NKG2DL, or NKG2D ligands, through a chimeric antigen receptor grafted onto gamma delta T cells. The product is allogeneic, meaning the T cells come from a donor rather than the patient. This NKG2DL-targeting approach is being evaluated in advanced cancers.
CTM-N2D is being developed by CytoMed Therapeutics Limited, which trades under the ticker GDTC. The company is advancing the allogeneic NKG2DL-targeting CAR-grafted gamma delta T cell therapy in a Phase 1 clinical trial.
CTM-N2D is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any regulatory authority. The ongoing Phase 1 trial is currently recruiting participants.
CTM-N2D is being evaluated in a single Phase 1 trial, NCT05302037, titled Allogeneic NKG2DL-targeting CAR gamma delta T Cells (CTM-N2D) in Advanced Cancers (ANGELICA). The trial is recruiting up to 12 participants in Singapore and is controlled, non-randomized, and not double-blind.